Molecular Subtype
B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1
CI-CAN-00004535Explore in graph →
Hematologic18 active trials4 evidence items
- NCIt
- C80331
- OncoTree
- BLLBCRABL1
- DOID
- 0080643
- UMLS CUI
- C2698317
Loading cancer entity…
Molecular Subtype
CI-CAN-00004535Explore in graph →
Clinical trials
39 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05931757 | A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL | not yet recruiting | Phase 2 | 22 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jul 5, 2023source: clinicaltrials